Pulse Bioscience News Today

HAYWARD, Calif.--(BUSINESS WIRE)--May 16, 2024--

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, today announced that the Company’s Board of Directors has set the...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, today announced business updates and financial results for the...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, today announced that its Board of Directors has unanimously approved...

Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion The...

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today...

Pulse Biosciences, Inc. announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully...

Pulse Biosciences (Nasdaq:PLSE) today announced the completion of the first-in-human procedures for its CellFX nsPFA cardiac catheter.

Operator: Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Renowned Cardiothoracic Surgeon to Join Experienced Medical Device Technology Leadership Team to Bring nsPFA to Cardiac Surgery ...